Rejuvenate Biomed, a biomedical company researches the biology of aging & applying this knowledge to identify safe and well tolerated combination drugs to maintain and restore our natural cell resilience, improving the response to age-related diseases
As action to the COVID-19 outbreak, we are assessing the potential difference RJx-01, our safe and well tolerated combination drug, can make.
Biology of aging
Major progress has been made in the biology of aging also known as geroscience. This has resulted in a better scientific understanding of the biological processes associated with age-related functional decline. Several mechanisms have been elucidated and drugable targets have been identified.
We identify opportunities to impact the aging process by repositioning Rx products. Our portfolio currently contains 7 individual compounds, selected via our Pre-Clinical and Clinical AI platform focusing on safety and their efficacy potential. Based on the succesful preclinical data, we are preparing our lead candidate for a POC study, starting in 2021.
Lead compound RJx-01
Our lead candidate RJx-01, and first entry into market, is a combination product indicated to treat Sarcopenia (muscle failure). Sarcopenia is the progressive loss of skeletal muscle quality / mass and strength. It affects 2-24% of the overall population, and 50% of 80 year old. It increases the risk of physical disability, poor quality of life and death.